Navigation Links
Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
Date:12/26/2007

ROCKVILLE, Md., Dec. 26 /PRNewswire/ -- Sirnaomics, Inc. announced today that the company has received funding from a variety of Government Programs. Sirnaomics, Inc. (http://www.sirnaomics.com), a biopharmaceutical company founded in early 2007, dedicates to advancing RNA interference (RNAi) Technology for novel drug discovery and targeted therapeutics development. The company's multi-targeted siRNA therapeutic programs and its nanoparticle-enhanced delivery technologies represent the unique approach for truly realizing advantages of small interfering RNA (siRNA)-based drugs, to treat various critical human diseases. Sirnaomics has been successfully attracting grants and investments from the State of Maryland, Department of Business and Economics Development (DBED), Maryland Industrial Partnerships (MIPS) and the Montgomery County Technology Growth Programs (TGP), in addition to the State of Maryland Tax Credit Program for Biotechnology Investment.

RNAi has emerged as a fundamentally important biological phenomenon and as a versatile, powerful tool for biomedical research. RNAi plays a multifaceted role in molecular biology by silencing genes through chromatin remodeling, interfering with protein synthesis, and in its best-studied mode of action quashing gene expression by cleaving messenger RNA. Experimental applications of RNAi have spurred the exploration of gene function in many basic research, drug discovery and clinical settings. The 2006 Nobel Prize for medicine and physiology and a number of corporate acquisitions and investments by Novartis, Merck, AstraZeneca and Roche injecting billions of dollars into this novel technology further fueled the enthusiasm for the great promise of siRNA therapeutics development.

Sirnaomics' mission is to advance RNAi technology with the proprietary positions on multi-targeted siRNA cocktail design and nanoparticle-mediated siRNA delivery for novel therapeutics. The company is dedicated to becoming the leader in the field of RNAi technology by spearheading into the targeted therapeutics market. The company's partnership with big pharmas and major biotech companies, along with government funding and venture capital financing, will strengthen its financial resources to accelerate the development of the technology platforms and siRNA therapeutic products. The strong ties with biopharmaceutical communities in Asia (China) allow the company to speed up its pre-clinical and clinical processes for novel siRNA therapeutic development with low cost. The company's proprietary "Tri-Blocker" technology for multi-targeted siRNA cocktail design and "Snano" series of nanoparticle delivery systems enable its advanced RNAi therapeutic programs for treatment of various critical human conditions including aging diseases, infectious diseases and cancer. The leading product, STP601, a multi-targeted siRNA cocktail therapeutics for treatment of ocular neovascularization such as AMD, PDR and HSK, is expected to be in clinic in 2008, in addition to an enriched product pipeline of siRNA therapeutics. Since the summer of 2007, Sirnaomics has received a number of angel investments related to the State of Maryland Tax Credit Programs for Biotechnology Investment. The company has also received the TGP grant from Montgomery County and has recently been awarded a two-year MIPS grant jointly with Professor James Mixson of University of Maryland. In addition, the company has also received an investment from the State of Maryland DBED Challenge Investment Fund.

"The Governmental fundings play the critical role in Sirnaomics early stage financing," said the founder, President and CEO of the company, Dr. Patrick Y. Lu. "It not only supplies initial fuel for us to take off, but more importantly provides solid foundation for our staged financing strategy, to ensure the long term health of the company's financial structure." Dr. Lu further emphasized that the Sirnaomics case clearly reflects the governmental effort in providing favorable environment for biotech ventures and entrepreneurships in the State of Maryland. "Partnering with pharma and major biotech companies and obtaining venture capital investment will further strengthen Sirnaomics financial resource to allow us to validate the multi- targeted siRNA therapeutic approach in human," Lu said.

Sirnaomics, Inc. is a privately held Delaware corporation headquartered in Gaithersburg, Maryland, USA. Established by a group of leading scientists in the field of RNAi technology, the company has the mission of advancing RNAi technology for novel drug discovery and targeted therapeutics development. Members of the senior management come with over 50 years of combined experiences in both biopharmaceutical industry and finance and business management, to ensure the healthy growth of Sirnaomics as an international biopharmaceutical enterprise. The name of the company Sirnaomics (/ser-'now-miks/) is derived from the tech word "siRNA" with the suffix "-omics" to signify the study of the structure and function of small interfering RNA including their silencing properties and complex interplay with the targeted sequences inside cells.

Contact:

Patrick Y. Lu, Ph.D.

Sirnaomics, Inc.

401 Professional Drive, Suite 130

Gaithersburg, MD 20879, USA

240-606-5039

301-869-2633 FAX

info-office@sirnaomics.com

http://www.sirnaomics.com


'/>"/>
SOURCE Sirnaomics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
4. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
5. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
6. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
7. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. HollisterStier Offers Comfort With New ComforTen(TM) Multiple Skin Testing Device
10. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
11. New Report Analyzes Key Controversies in Multiple Sclerosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory ... technical consulting, provides a free webinar on Performing Quality Investigations: Getting ... at 12pm CT at no charge. , Incomplete investigations are still a major ...
(Date:6/23/2016)... -- Amgen (NASDAQ: AMGN ) today announced a ... sciences incubator to accelerate the development of new therapies ... QB3@953 was created to help high-potential life science and ... stage organizations - access to laboratory infrastructure. ... "Amgen Golden Ticket" awards, providing each winner with one ...
(Date:6/22/2016)... 22, 2016 Cell Applications, Inc. and ... to produce up to one billion human induced ... one week. These high-quality, consistent stem cells enable ... and spend more time doing meaningful, relevant research. ... high-volume manufacturing process that produces affordable, reliable HiPSC ...
(Date:6/22/2016)... YORK , June 22, 2016  According ... growing next generation sequencing (NGS) market include significant ... of smaller sequencers.  More accessible and affordable sequencers, ... to growing demand for consumables including sample prep ... The Market for Sample Preparation for Next Generation ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):